SFE Investment Counsel Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

SFE Investment Counsel purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 4,900 shares of the company’s stock, valued at approximately $307,000.

Other large investors have also recently modified their holdings of the company. CWM LLC increased its stake in CRISPR Therapeutics by 80.7% during the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after purchasing an additional 260 shares in the last quarter. Tradewinds Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 545.5% in the 3rd quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after acquiring an additional 600 shares during the last quarter. Blue Trust Inc. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $32,000. Headlands Technologies LLC purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at $34,000. Finally, Bourgeon Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 1,000.0% in the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 0.3 %

Shares of NASDAQ CRSP opened at $56.00 on Friday. The company’s 50-day simple moving average is $73.51 and its 200-day simple moving average is $63.34. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. The business’s quarterly revenue was up 3253.3% on a year-over-year basis. During the same period in the prior year, the business posted ($1.41) earnings per share. Equities analysts expect that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now directly owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The disclosure for this sale can be found here. Over the last three months, insiders have sold 133,992 shares of company stock valued at $9,157,835. Corporate insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

CRSP has been the topic of several recent research reports. Wells Fargo & Company upped their price objective on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a report on Thursday, February 22nd. Citigroup upped their price objective on shares of CRISPR Therapeutics from $88.00 to $89.00 and gave the company a “buy” rating in a report on Thursday. Wolfe Research began coverage on shares of CRISPR Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Royal Bank of Canada increased their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Finally, Mizuho increased their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $76.29.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.